StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Research analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Alliance Global Partners lifted their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $0.15 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The firm’s fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $3.69. Tonix Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $27.97. The stock has a market capitalization of $3.30 million, a P/E ratio of 0.00 and a beta of 2.09.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing the consensus estimate of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. The business had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. As a group, analysts predict that Tonix Pharmaceuticals will post -12.37 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.